Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

1.

Converging Goals of Treatment for Inflammatory Bowel Disease, from Clinical Trials and Practice.

Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF.

Gastroenterology. 2014 Aug 12. pii: S0016-5085(14)00999-8. doi: 10.1053/j.gastro.2014.08.003. [Epub ahead of print] Review.

PMID:
25127678
[PubMed - as supplied by publisher]
2.

Comment on 'anti-adhesion therapies and the rule of 3 for rare events'.

Feagan BG, Colombel JF, Hanauer SB, Parikh A, Rutgeerts P, Sandborn WJ, Sands BE.

Am J Gastroenterol. 2014 Jul;109(7):1083-4. doi: 10.1038/ajg.2014.117. No abstract available.

PMID:
24989100
[PubMed - indexed for MEDLINE]
3.

Anti-TNFα therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis.

Narula N, Al-Dabbagh R, Dhillon A, Sands BE, Marshall JK.

Inflamm Bowel Dis. 2014 Oct;20(10):1862-9. doi: 10.1097/MIB.0000000000000092.

PMID:
24983985
[PubMed - in process]
4.

Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.

Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S.

Gastroenterology. 2014 Sep;147(3):618-627.e3. doi: 10.1053/j.gastro.2014.05.008. Epub 2014 May 21.

PMID:
24859203
[PubMed - indexed for MEDLINE]
Free Article
5.

Fatigue is highly associated with poor health-related quality of life, disability and depression in newly-diagnosed patients with inflammatory bowel disease, independent of disease activity.

Cohen BL, Zoëga H, Shah SA, Leleiko N, Lidofsky S, Bright R, Flowers N, Law M, Moniz H, Merrick M, Sands BE.

Aliment Pharmacol Ther. 2014 Apr;39(8):811-22. doi: 10.1111/apt.12659. Epub 2014 Feb 20.

PMID:
24612278
[PubMed - indexed for MEDLINE]
Free Article
6.

SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease.

Fowler SA, Ananthakrishnan AN, Gardet A, Stevens CR, Korzenik JR, Sands BE, Daly MJ, Xavier RJ, Yajnik V.

J Crohns Colitis. 2014 Aug 1;8(8):845-51. doi: 10.1016/j.crohns.2014.01.003. Epub 2014 Jan 24.

PMID:
24461721
[PubMed - in process]
7.

Menstrual cycle changes in women with inflammatory bowel disease: a study from the ocean state Crohn's and colitis area registry.

Saha S, Zhao YQ, Shah SA, Esposti SD, Lidofsky S, Salih S, Bright R, Law M, Moniz H, Flowers N, Merrick M, Sands BE.

Inflamm Bowel Dis. 2014 Mar;20(3):534-40. doi: 10.1097/01.MIB.0000441347.94451.cf.

PMID:
24451220
[PubMed - indexed for MEDLINE]
8.

Challenges in designing a national surveillance program for inflammatory bowel disease in the United States.

Long MD, Hutfless S, Kappelman MD, Khalili H, Kaplan GG, Bernstein CN, Colombel JF, Gower-Rousseau C, Herrinton L, Velayos F, Loftus EV Jr, Nguyen GC, Ananthakrishnan AN, Sonnenberg A, Chan A, Sandler RS, Atreja A, Shah SA, Rothman KJ, Leleiko NS, Bright R, Boffetta P, Myers KD, Sands BE.

Inflamm Bowel Dis. 2014 Feb;20(2):398-415. doi: 10.1097/01.MIB.0000435441.30107.8b.

PMID:
24280882
[PubMed - in process]
9.

Vedolizumab as induction and maintenance therapy for Crohn's disease.

Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group.

N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739.

PMID:
23964933
[PubMed - indexed for MEDLINE]
Free Article
10.

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group.

N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734.

PMID:
23964932
[PubMed - indexed for MEDLINE]
Free Article
11.

Reliability and initial validation of the ulcerative colitis endoscopic index of severity.

Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Schnell P, Bernhardt CA, Mary JY, Sandborn WJ.

Gastroenterology. 2013 Nov;145(5):987-95. doi: 10.1053/j.gastro.2013.07.024. Epub 2013 Jul 25.

PMID:
23891974
[PubMed - indexed for MEDLINE]
Free Article
12.

Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center.

Tinsley A, Naymagon S, Enomoto LM, Hollenbeak CS, Sands BE, Ullman TA.

J Crohns Colitis. 2013 Dec 15;7(12):e635-40. doi: 10.1016/j.crohns.2013.05.002. Epub 2013 May 22.

PMID:
23706933
[PubMed - indexed for MEDLINE]
13.

Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study.

Herfarth HH, Katz JA, Hanauer SB, Sandborn WJ, Loftus EV Jr, Sands BE, Galanko JA, Walkup D, Isaacs KL, Martin CF, Sandler RS, Sartor RB.

Inflamm Bowel Dis. 2013 Apr;19(5):1073-9. doi: 10.1097/01.MIB.0000428910.36091.10.

PMID:
23511031
[PubMed - indexed for MEDLINE]
14.

The risks and benefits of early immunosuppression and biological therapy.

Sands BE.

Dig Dis. 2012;30 Suppl 3:100-6. doi: 10.1159/000342731. Epub 2013 Jan 3. Review.

PMID:
23295699
[PubMed - indexed for MEDLINE]
15.

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG; CERTIFI Study Group.

N Engl J Med. 2012 Oct 18;367(16):1519-28. doi: 10.1056/NEJMoa1203572.

PMID:
23075178
[PubMed - indexed for MEDLINE]
Free Article
16.

Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment.

Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ, Huttenhower C.

Genome Biol. 2012 Apr 16;13(9):R79. doi: 10.1186/gb-2012-13-9-r79.

PMID:
23013615
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease.

Sands BE, Katz S, Wolf DC, Feagan BG, Wang T, Gustofson LM, Wong C, Vandervoort MK, Hanauer S.

Gut. 2013 Sep;62(9):1288-94. doi: 10.1136/gutjnl-2011-300995. Epub 2012 Jul 3.

PMID:
22760005
[PubMed - indexed for MEDLINE]
18.

A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease.

Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH, Blank M, Montello J, Tang L, Cornillie F, Colombel JF.

Am J Gastroenterol. 2012 Jul;107(7):1051-63. doi: 10.1038/ajg.2012.89. Epub 2012 May 22.

PMID:
22613901
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP; Secukinumab in Crohn's Disease Study Group.

Gut. 2012 Dec;61(12):1693-700. doi: 10.1136/gutjnl-2011-301668. Epub 2012 May 17.

PMID:
22595313
[PubMed - indexed for MEDLINE]
20.

Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis.

Sands BE, Sandborn WJ, Creed TJ, Dayan CM, Dhanda AD, Van Assche GA, Greguš M, Sood A, Choudhuri G, Stempien MJ, Levitt D, Probert CS.

Gastroenterology. 2012 Aug;143(2):356-64.e1. doi: 10.1053/j.gastro.2012.04.043. Epub 2012 Apr 28.

PMID:
22549092
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk